Review ArticleReview

Adapting to Biology: Maintaining Container–Closure System Compatibility with the Therapeutic Biologic Revolution

Dominick Degrazio
PDA Journal of Pharmaceutical Science and Technology March 2015, 69 (2) 219-235; DOI: https://doi.org/10.5731/pdajpst.2015.01032

References

  1. 1.↵
    1. Ukraintseva S.V.,
    2. Yashin A. I.
    Individual aging and cancer risk: How are they related? Demographic Research 2003, 9 (8), 163–196.
    OpenUrl
  2. 2.↵
    1. Leader B.,
    2. Baca Q. J.,
    3. Golan D. E.
    Protein therapeutics: a summary and pharmacological classification. Nat. Rev. Drug Discov. 2008, 7 (1), 21–39.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. van Beers M. M.,
    2. Bardor M.
    Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins. Biotech. J. 2012, 7 (12), 1473–1484.
    OpenUrl
  4. 4.↵
    1. Schellekens H.
    Follow-on biologics: challenges of the ǹext generation'. Nephrol. Dial. Transplant. 2005, 20 (Suppl. 4), iv31–iv36.
    OpenUrlAbstract
  5. 5.↵
    U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for Industry—Early clinical trials with live biotherapeutic products: Chemistry, manufacturing, and control information, 2012.
  6. 6.↵
    1. Bee J. S.,
    2. Nelson S. A.,
    3. Freund E.,
    4. Carpenter J. F.,
    5. Randolph T. W.
    ; Precipitation of a monoclonal antibody by soluble tungsten. J. Pharm. Sci. 2009, 98 (9), 3290–3301.
    OpenUrlCrossRefPubMed
  7. 7.↵
    U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry—Immunogenicity assessment for therapeutic protein products, 1999.
  8. 8.↵
    U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry—Container closure systems for packaging human drugs and biologics, 1999.
  9. 9.↵
    1. Baumann A.
    Early development of therapeutic biologics—pharmacokinetics. Curr. Drug Metab. 2006, 7 (1), 15–21.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Kuriyan J.,
    2. Konforti B.,
    3. Wemmer D.
    The Molecules of Life: Physical and Chemical Principles, 1st ed.; Garland Science: New York, 2013; p 28.
  11. 11.↵
    1. Lins L.,
    2. Brasseur R.
    The hydrophobic effect in protein folding. FASEB J. 1995, 9 (7), 535–540.
    OpenUrlAbstract
  12. 12.↵
    1. Petsko G. A.,
    2. Ringe D.
    Protein Structure and Function: Primers in Biology, 1st ed.; Sinauer Assoc. Inc.: London, 2003; p 23.
  13. 13.↵
    1. Zhou S.,
    2. Lewis L.,
    3. Singh S. K.
    Metal leachables in therapeutic biologic products: origin, impact and detection. Am. Pharm. Rev. 2010, 13 (4), 76.
    OpenUrl
  14. 14.↵
    1. Gummadi S. N.
    What is the role of thermodynamics on protein stability? Biotechnol. Bioprocess Eng. 2003, 8 (1), 9–18.
    OpenUrl
  15. 15.↵
    1. Harano Y.
    Application of hydration thermodynamics to the evaluation of protein structures and protein-ligand binding. Entropy 2012, 14 (8), 1443–1468.
    OpenUrl
  16. 16.↵
    1. Yasuda S.,
    2. Oshima H.,
    3. Kinoshita M.
    Structural stability of proteins in aqueous and nonpolar environments. J. Chem. Phys 2012, 137 (13), 135103.
    OpenUrlPubMed
  17. 17.↵
    1. Chi E. Y.,
    2. Krishnan S.,
    3. Kendrick B. S.,
    4. Chang B. S.,
    5. Carpenter J. F.,
    6. Randolph T. W.
    Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor. Protein Sci. 2003, 12 (5), 903–913.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Change B.S.,
    2. Yeung B.
    Physical Stability of Protein Pharmaceuticals. In Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals, 1st ed.; Wiley Inc.: New York, 2010; p 69.
  19. 19.↵
    1. Patel J.,
    2. Kothari R.,
    3. Tunga R.,
    4. Ritter N. M.,
    5. Tunga B. S.
    Stability considerations for biopharmaceuticals, Part 1: Overview of protein and peptide degradation pathways. BioProcess Int. 2011, 9 (1), 20–31.
    OpenUrl
  20. 20.↵
    1. Powell M. F.
    Peptide Stability in Aqueous Parenteral Formulations: Prediction of Chemical Stability Based on Primary Sequence. In Formulation and Delivery of Proteins and Peptides, 1st ed.; ACS Symposium, 1994, p 100.
  21. 21.↵
    1. Li S.,
    2. Nguyen T. H.,
    3. Schoneich C.,
    4. Borchardt R. T.
    Aggregation and precipitation of human relaxin induced by metal-catalyzed oxidation. Biochemistry 34 (17), 5762–5772.
  22. 22.↵
    1. Chirmule N.,
    2. Jawa V.,
    3. Meibohm B.
    Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J. 2012, 14 (2), 296–302.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Jiskoot W.,
    2. Randolph T. W.,
    3. Volkin D. B.,
    4. Middaugh C. R.,
    5. Schoneich C.,
    6. Winter G.,
    7. Friess W.,
    8. Crommelin D. J.,
    9. Carpenter J. F.
    Protein instability and immunogenicity: Roadblocks to clinical application of injectable protein delivery systems for sustained release. J. Pharm. Sci. 2012, 101 (3), 946–954.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Brennan T.V.,
    2. Clarke S.
    Deamidation and Isoaspartate Formation in Model Synthetic Peptides: The Effects of Sequence and Solution Environment. In Deamidation and Isoaspartate Formation in Peptides and Proteins, 1st ed.; CRC Press: Boca Raton, FL, 1995; p 65.
  25. 25.↵
    1. Patel K.,
    2. Borchardt R. T.
    Chemical pathways of peptide degradation. II. Kinetics of deamidation of an asparaginyl residue in a model hexapeptide. Pharm. Res. 1990, 7 (7), 703–711.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Xie M.,
    2. Schowen R. L.
    Secondary structure and protein deamidation. J. Pharm. Sci. 1999, 88 (1), 8–13.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Robinson N. E.
    Protein deamidation. Proc. Nat. Soc. Sci. 2002, 99 (8), 5283–5288.
    OpenUrl
  28. 28.↵
    1. Miyata T.
    1. Monnier V. M.,
    2. Nemet I.,
    3. Sell D. R.,
    4. Weiss M. F.
    Transition Metals and Other Forms of Oxidative Protein Damage in Renal Disease. In Studies on Renal Disorders, Oxidative Stress in Applied Basic Research and Clinical Practice, 1st ed.; Miyata T., Ed.; Springer; New York, 2011; p 25.
  29. 29.↵
    1. Shacter E.
    Quantification and significance of protein oxidation in biological samples. Drug Metab. Rev. 2000, 32 (3–4), 307–326.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Li S.,
    2. Schöneich C.,
    3. Borchardt R. T.
    Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotech. Bioeng. 1995, 48 (5), 490–500.
    OpenUrl
  31. 31.↵
    1. Stadtman E. R.
    Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Ann. Rev. Biochem. 1993, 62 (1), 797–821.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Gsponer J.,
    2. Vendruscolo M.
    Theoretical approaches to protein aggregation. Protein Pept. Lett. 2006, 13 (3), 287–293.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    1. Philo J. S.,
    2. Arawaka T.
    Mechanisms of protein aggregation. Curr. Pharm. Biotechnol. 2009, 10 (4), 348–351.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Borgia M. B.,
    2. Nickson A. A.,
    3. Clarke J.,
    4. Hounslow M. J.
    A mechanistic model for amorphous protein aggregation of immunoglobulin -like domains. J. Am. Chem. Soc. 2013, 135 (17), 6456–6464.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Stranks S.,
    2. Ecroyd H.,
    3. Van Slutyer S.,
    4. Waters E. J.,
    5. Carver J. A.,
    6. von Smekal L.
    Model for amorphous aggregation processes. Phys. Rev. E Stat. Nonlin. Soft Matter Phys. 2009, 80 (5), 051907.
  36. 36.↵
    1. Morris A. M.,
    2. Watzky M. A.,
    3. Finke R. G.
    Protein aggregation kinetics, mechanism, and curve-fitting: a review of the literature. Biochim. Biophys. Acta 2009, 1794 (3), 375–397.
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.↵
    1. Sleutel M.,
    2. Van Driessche A. E. S.,
    3. Pan W.,
    4. Reichel E. K.,
    5. Maes D.,
    6. Vekilow P. G.
    Does solution viscosity scale the rate of aggregation of folding proteins? J. Phys. Chem. Lett. 2012, 3 (10), 1258–1263.
    OpenUrlCrossRef
  38. 38.↵
    1. Beerten J.,
    2. Schymkowitz J.,
    3. Rousseau F.
    Aggregation prone regions and gatekeeping residues in protein sequences. Curr. Top. Med. Chem. 2012, 12 (22), 2470–2478.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Rousseau F.,
    2. Schymkowitz J.,
    3. Serrano L.
    Protein aggregation and amyloidosis: confusion of the kinds? Curr. Opin. Struc. Biol. 2006, 16 (1), 118–126.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Linding R.,
    2. Schymkowitz J.,
    3. Rousseau F.,
    4. Diella F.,
    5. Serrano L.
    A comparative study of the relationship between protein structure and beta-aggregation in globular and intrinsically disordered proteins. J. Mol. Biol. 2004, 342 (1), 345–353.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    1. Baldwin R. L.,
    2. Frieden C.,
    3. Rose G. D.
    Dry molten globule intermediates and the mechanism of protein unfolding. Proteins 2010, 78 (13), 2725–2737.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    1. Roseberg A. S.
    Effects of protein aggregates: an immunologic perspective. AAPS J. 2006, 8 (3), E501–E507.
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    1. Kayser O.,
    2. Muller R. H.
    1. Meibohm B.,
    2. Derendorf H.
    Pharmacokinetics and Pharmacodynamics of Biotech Drugs. In Pharmaceutical Biotechnology, Drug Discovery, and Clinical Applications; Kayser O., Muller R. H., Eds.; Wiley-VCH Verlag GmbH: New York, 2004.
  44. 44.↵
    1. Crommelin D. J. A.,
    2. Sindelar R. D.,
    3. Meibohm B.
    1. Meibohm B.,
    2. Braeckman R. A.
    Pharmacokinetics and Pharmacodynamics of Peptides and Proteins. In Pharmaceutical Biotechnology: Concepts and Applications, 3rd ed.; Crommelin D. J. A., Sindelar R. D., Meibohm B., Eds; Informa Healthcare: New York, 2007; p 95.
  45. 45.↵
    1. Schellekens H.
    Immunogenicity of therapeutic proteins. Nephrol. Dial. Transplant. 2003, 18 (7), 1257–1259.
    OpenUrlFREE Full Text
  46. 46.↵
    1. Purcell R. T.,
    2. Lockey R. F.
    Immunologic responses to therapeutic biologic agents. J. Investig. Allergol. Clin. Immunol. 2008, 18 (5), 335–342.
    OpenUrlPubMed
  47. 47.↵
    1. Tang L.,
    2. Persky A. M.,
    3. Hochhaus G.,
    4. Meibohm B.
    Pharmacokinetic aspects of biotechnology products. J. Pharm. Sci. 2004, 93 (9), 2184–2204.
    OpenUrlCrossRefPubMedWeb of Science
  48. 48.↵
    1. Vugmeyster Y.,
    2. Xu X.,
    3. Theil F.-P.,
    4. Khawli L. A.,
    5. Leach M. W.
    Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges. World J. Biol. Chem. 2012, 3 (4) 73–92.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Wang W.,
    2. Wang E. Q.,
    3. Balthasar J. P.
    Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 2008, 84 (5), 548–558.
    OpenUrlCrossRefPubMedWeb of Science
  50. 50.↵
    1. Haynes C. A.,
    2. Norde W.
    Globular proteins at solid/liquid interfaces. Colloid. Surf., B Biointerfaces 1994, 2 (6), 517–566.
    OpenUrl
  51. 51.↵
    1. Brash J. L.,
    2. Wojciechowski P. W.
    1. Norde W.,
    2. Haynes C. A.
    Thermodynamics of Protein Adsorption. In Interfacial Phenomena and Bioproducts, Bioprocess Technology Series; Brash J. L., Wojciechowski P. W., Eds.; Marcel Dekker: New York, 1996; p 123.
  52. 52.↵
    1. Vogler E. A.
    Protein adsorption in three dimensions. Biomaterials 2012, 33 (5), 1201–1237.
    OpenUrlPubMed
  53. 53.↵
    1. Dixit N.,
    2. Maloney K. M.,
    3. Kalonia D. S.
    Effect of processing parameters on the physical stability of silicone coatings. AAPS PharmSciTech 2012, 13 (4), 1116–1119.
    OpenUrlPubMed
  54. 54.↵
    1. Badkar A.,
    2. Wolf A.,
    3. Bohack L.,
    4. Kolhe P.
    Development of biotechnology products in pre-filled syringes: technical considerations and approaches. AAPS PharmSciTech 2011, 12 (2), 564–572.
    OpenUrlPubMed
  55. 55.↵
    1. Liu L.,
    2. Ammar D. A.,
    3. Ross L. A.,
    4. Mandava N.,
    5. Kahook M. Y.,
    6. Carpenter J. F.
    Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest. Ophthalmol. Vis. Sci. 2011, 52 (2), 1023–1034.
    OpenUrlAbstract/FREE Full Text
  56. 56.↵
    1. Seidl A.,
    2. Hainzl O.,
    3. Richter M.,
    4. Fischer R.,
    5. Bohm S.,
    6. Deutel B.,
    7. Hartinger M.,
    8. Windisch J.,
    9. Casadevall N.,
    10. London G. M.,
    11. Macdougall I.
    Tungsten-induced denaturation and aggregation of epoetin alpha during primary packaging as a cause of immunogenicity. Pharm. Res. 2012, 29 (6), 1454–1467.
    OpenUrlCrossRefPubMed
  57. 57.↵
    1. Greenwood N. N.,
    2. Earnshaw A.,
    3. Greenwood N.
    Chemistry of the Elements, 2nd ed.; Elsevier Butterworth-Heinemann: Burlington, MA, 1997.
  58. 58.↵
    1. Ball D. J.,
    2. Norwood D. L.,
    3. Stults C. L. M.,
    4. Nagao L. M.
    Leachables and Extractables Handbook: Safety Evaluation, Qualification, and Best Practices Applied to Inhalation Drug Products; Wiley Inc.: Hoboken, NJ, 2012; p 29.
  59. 59.↵
    1. Kehrer J. P.
    The Haber-Weiss reaction and mechanisms of toxicity. Toxicology 2000, 149 (1), 43–50.
    OpenUrlCrossRefPubMedWeb of Science
  60. 60.↵
    1. Hawkins C. L.,
    2. Pattison D. I.,
    3. Davies M. J.
    Hypochlorite-induced oxidation of amino acids, peptides and proteins. Amino Acids 2003, 25 (2–3), 259–274.
    OpenUrlCrossRefPubMedWeb of Science
  61. 61.↵
    1. Liu D.,
    2. Nashed-Samuel Y.,
    3. Bondarenko P. V.,
    4. Brems D. N.,
    5. Ren D.
    Interactions between therapeutic proteins and acrylic acid leachable. PDA J. Pharm. Sci. and Technol. 2012, 66 (1), 12–19.
    OpenUrl
  62. 62.↵
    1. LoPachin R. M.,
    2. Barber D.,
    3. Gavin T.
    Molecular mechanisms of the conjugated α,β-unsaturated carbonyl derivatives: Relevance to neurotoxicity and neurodegenerative diseases. Toxicological Sci. 2008, 104 (2), 235–249.
    OpenUrlAbstract/FREE Full Text
  63. 63.↵
    1. Elfarra A. A.
    1. Elfarra A. A.,
    2. Krause R. J.
    Michael Addition–Elimination Reactions: Roles in Toxicity and Potential New Therapeutic Applications. In Advances in Bioactivation Research; Elfarra A. A. Ed.; Springer; New York, 2008, p 57.
Back to top

In This Issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Adapting to Biology: Maintaining Container–Closure System Compatibility with the Therapeutic Biologic Revolution
Dominick Degrazio
PDA Journal of Pharmaceutical Science and Technology Mar 2015, 69 (2) 219-235; DOI: 10.5731/pdajpst.2015.01032
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords